A Phase II Trial of VP-16, Ifosfamide and Cisplatin (VIP) Combination Chemotherapy for Previously Untreated Extensive Small Cell Lung Cancer

Abstracts/Posters/Presentations:

• Miller JC, Loehrer PJ, Songer J, Pennington K, Ansari R, Turner S, Einhorn LH: VP l6, Ifosfamide and Cisplatin (VIP) in Extensive Small Cell Lung Cancer: A Hoosier Oncology Group Study LUN87-1. Proc Am Soc Clin Oncol 9:248, l990.
• Faylona E, Loehrer P, Einhorn L, Ansari R, McClean J, Williams S: A Phase II Study of Daily Oral VP-16 + Ifosfamide + Cisplatin for Previously Treated Small Cell Lung Cancer (SCLC): A Hoosier Oncology Group Study (HOG) Trial LUN87-1. Proc Am Soc Clin Oncol, 1992.
• Sandler AB, Loehrer PJ, Ansari R, Logie KW, Mortimer J, Sridhar R, Einhorn LH. A Phase II Study of Daily Oral VP-16 Plus Ifosfamide Plus Cisplatin (poVIP) for Previously Treated Recurrent Small Cell Lung Cancer (SCLC): A Hoosier Oncology Group and Walther Cancer Institute Trial LUN87-1. Poster Presentation accepted to the ASCO Annual Meeting, May 14-17, 1994, Dallas, Texas.
• Sandler AB, Ansari R, Fisher W, Gonin R, Levy R, Einhorn LH. A Phase II Hoosier Oncology Group Study of VP-16 Plus Ifosfamide Plus Cisplatin (VIP) Plus Concurrent Radiation Therapy (XRT) for Previously Untreated Limited Small Cell Lung Cancer (SCLC). A Hoosier Oncology Group and Walther Cancer Institute Trial LUN87-1. Accepted to the World Conference on Lung Cancer August, 1997 Dublin, Ireland.

Manuscripts/Articles:

• Loehrer PJ, Rynard SM, Ansari R, Songer J, Pennington K, Einhorn LH: Etoposide Plus Ifosfamide Plus Cisplatin (VIP) in Extensive Small-cell Lung Cancer LUN87-1. Cancer 69:669-673, 1992